Pfizer (PFE) Cash from Operations (2009 - 2026)

Pfizer (PFE) has reported Cash from Operations for 18 consecutive years, with $835.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 243.47% year-over-year to $835.0 million in Q2 2026; TTM through Jun 2026 was $13.4 billion, a 123.54% increase from a year earlier, with the FY2025 full-year figure at $11.7 billion, down 8.16% from the prior year.
• Cash from Operations was $835.0 million for Q2 2026 at Pfizer, down from $2.6 billion in the prior quarter.
• Over five years, Cash from Operations peaked at $8.2 billion in Q3 2022 and troughed at -$1.8 billion in Q2 2024.
• A 5-year average of $2.9 billion and a median of $2.5 billion in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 114.77% in 2023 and soared 243.47% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at $8.2 billion in 2022, then tumbled by 35.91% to $5.2 billion in 2023, then increased by 14.94% to $6.0 billion in 2024, then retreated by 11.21% to $5.3 billion in 2025, then tumbled by 84.39% to $835.0 million in 2026.
• The last three Cash from Operations figures came in at $835.0 million (Q2 2026), $2.6 billion (Q1 2026), and $5.3 billion (Q4 2025), per Business Quant data.